APLN and metabolic disease: Importantly, chronic oral administration of 1 μM apelin-13 reverses duodenal hypercontractility, lowers glucose absorption, and improves insulin sensitivity in obese/diabetic mice (Fournel et al., 2017), indicating a potential for apelin as an oral therapeutic in metabolic disease.